Horse Chestnut for Anti-Inflammatory

Research suggests that horse chestnut and its primary active compound escin (also called aescin) demonstrate meaningful anti-inflammatory properties across a range of study types, including pharmacological reviews, animal models, cell culture experiments, and clinical overviews, with the overall body of evidence pointing in a consistently supportive direction. Studies indicate that escin reduces inflammation through several proposed mechanisms, including decreasing vascular permeability, suppressing inflammatory signaling molecules such as TNF-α, IL-1β, and IL-6, inhibiting the bradykinin pathway, and showing synergistic effects with glucocorticoids at low doses in animal models. Other compounds found in horse chestnut, including esculin and specific saponin fractions, have also shown anti-inflammatory activity in preclinical settings, and clinical reviews have noted moderate-quality evidence supporting its use for edema and inflammation associated with chronic venous insufficiency and related conditions. However, most of the mechanistic evidence comes from animal and laboratory studies rather than large randomized controlled trials, standardization of extracts remains a recognized challenge, and one review flagged potential interactions with analgesic drugs, so readers should be aware that the clinical evidence base, while promising, is not yet comprehensive.